Controversial ‘3-Parent Baby’ Fertility Technique Fails to Deliver for Older Women
By Emily Mullin,
Medium One Zero [cites CGS' Marcy Darnovsky]
| 10. 15. 2019
The experimental procedure is banned in the United States but is being offered at clinics abroad as a treatment for infertility.
An experimental and much-hyped reproductive procedure that mixes DNA from three people is not effective at boosting the chances of having a baby for women ages 37 and older, according to doctors at a fertility clinic in Ukraine.
The technique, known as mitochondrial replacement therapy, involves taking a woman’s egg and shifting the majority of its DNA, known as the nucleus, into a hollowed-out donor egg. The shell of the donor egg contains healthy mitochondria, energy-making structures that have their own DNA. The resulting embryo ends up with DNA from the mother, father, and egg donor, so the technique is often referred to as “three-person IVF.” The procedure is controversial because many consider it a form of genetic manipulation.
Some fertility experts hoped that the younger mitochondria from the hollowed-out donor egg might rejuvenate the eggs of an infertile woman, thus increasing the chances of a successful pregnancy.
But new study results presented at a meeting of the American Society of Reproductive Medicine in Philadelphia show that might not be the case. The three-person IVF procedure was found to be...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...